ERBB2 and breast cancer: Assess the rate of patients with persistent CTCs after randomization and treatment by 6 cycles of trastuzumab or observation, in subjects with HER2‐negative BC with ≥ 1/15mL (using the CellSearch® system) CTC after surgery and (neo)adjuvant chemotherapy